Global Anticancer Drugs Market Size study, By Drug Type - Cytotoxic Drugs (Alkylating Agents, and Antimetabolites), Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), and Hormonal Drugs), By Therapy Type (Chemotherapy, Targeted Therapy, and Immunotherapy), By Cancer Type (Lung Cancer, Breast Cancer, Leukemia, and Colorectal Cancer), and Regional Forecasts 2020-2027

  • Product Code:
    RP-ID-10346639
  • Published Date:
    21 Dec 2020
  • Region:
    Global
  • Pages:
    200
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-14

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

Global Anticancer Drugs Market is valued approximately at USD 105.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 6.7% over the forecast period 2020-2027. Sales of anti-cancer drugs are gaining momentum, as many awareness campaigns are being undertaken at global level by governments and central authorities. The National Breast Cancer Foundation, Inc. is undertaking an annual initiative to promote information on the disease by observing October as a month of recognition of breast cancer and encouraging women to undergo screening tests. Such programs are rising the number of diagnostics, unwittingly creating a large patient pool for anticancer drugs. The increase in funding to promote research and development of anticancer therapy is contributing to improvements in treatment methods and routes of administration. The creation of therapies with improved patient outcomes and less side-effects than traditional drugs is expected to increase patient confidence in these drugs and thus improve the growth potential of the market for anticancer drugs. Besides, the U.S. The Food and Drug Administration (FDA) determines the status of 'orphan drugs' for drugs that have a promising potential for the treatment of rare diseases. In order to further encourage the production of highly successful medicines for rare diseases such as cancer, the FDA provides benefits such as market exclusivity and tax credits for clinical trials. In the background of these dynamics, the demand for and availability of these drugs is expected to increase, thereby boosting the growth of the global market for anticancer drugs. Anti-cancer drug market sales are projected to rise by 50% over the next five years, primarily due to favorable regulatory scenarios in the U.S. According to the American Cancer Society, the number of deaths worldwide was 8.2 billion in 2012 and is projected to rise over the predicted period. Despite a dramatic increase in cancer diagnosis rates, the sales of anticancer drugs have yet to recognize their true potential. Growing understanding of the side-effects of anticancer treatment, such as hair loss, anemia, constipation, infection and neutropenia, sexual health problems, and bleeding and bruising, is expected to raise the consumer's inclination towards natural therapy. In regions such as Southeast Asia , the Middle East and Africa, India and China, patients are taking alternative therapeutic drugs such as Ayurveda, homoeopathic and herbal medicines, which could have a negative effect on the demand for anticancer drugs during the forecast period (2020-2027).
The regional analysis of global Anticancer Drugs Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is projected to grow at a rapid pace during the forecast period other than Japan and Australia, which appears to be favorable to business growth. Growing recognition of the advantages of early detection, growing disposable incomes, increasing prevalence of the number of types of cancer, and estimated pipeline drugs are driving the growth of the regional sector. Due to the easy availability of drugs in the region and high spending on healthcare from both the private and public sectors, North America is projected to make a major contribution to the global market for anti-cancer drugs. Apart from that, existing players are joining China and India because of the high prevalence of the market making it attractive. Markets in other regions, such as Africa , the Middle East and Latin America, are expected to expand at a moderate pace during the forecast period.

Major market player included in this report are:
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
Novartis AG
Pfizer Inc
Bayer AG
AstraZeneca
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
CELGENE CORPORATION
Amgen Inc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type:
Cytotoxic Drugs
Targeted Drugs
Hormonal Drugs

By Therapy Type:
Chemotherapy
Targeted Therapy
Immunotherapy
Others
By Cancer Type:
Lung Cancer
Breast Cancer
Leukaemia
Colorectal Cancer
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Anticancer Drugs Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. Anticancer Drugs Market, by Region, 2018-2027 (USD Billion)
1.2.2. Anticancer Drugs Market, by Drug Type, 2018-2027 (USD Billion)
1.2.3. Anticancer Drugs Market, by Therapy Type, 2018-2027 (USD Billion)
1.2.4. Anticancer Drugs Market, by Cancer Type, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Anticancer Drugs Market Definition & Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Anticancer Drugs Market Dynamics
3.1. Anticancer Drugs Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Anticancer Drugs Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Anticancer Drugs Market, by Drug Type
5.1. Market Snapshot
5.2. Global Anticancer Drugs Market by Drug Type, Performance - Potential Analysis
5.3. Global Anticancer Drugs Market Estimates & Forecasts by Drug Type, 2017-2027 (USD Billion)
5.4. Anticancer Drugs Market, Sub Segment Analysis
5.4.1. Cytotoxic Drugs
5.4.2. Targeted Drugs
5.4.3. Hormonal Drugs
Chapter 6. Global Anticancer Drugs Market, by Therapy Type
6.1. Market Snapshot
6.2. Global Anticancer Drugs Market by Therapy Type, Performance - Potential Analysis
6.3. Global Anticancer Drugs Market Estimates & Forecasts by Therapy Type, 2017-2027 (USD Billion)
6.4. Anticancer Drugs Market, Sub Segment Analysis
6.4.1. Chemotherapy
6.4.2. Targeted Therapy
6.4.3. Immunotherapy
6.4.4. Others
Chapter 7. Global Anticancer Drugs Market, by Cancer Type
7.1. Market Snapshot
7.2. Global Anticancer Drugs Market by Cancer Type, Performance - Potential Analysis
7.3. Global Anticancer Drugs Market Estimates & Forecasts by Cancer Type, 2017-2027 (USD Billion)
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Leukaemia
7.3.4. Colorectal Cancer
7.3.5. Others
Chapter 8. Global Anticancer Drugs Market, Regional Analysis
8.1. Anticancer Drugs Market, Regional Market Snapshot
8.2. North America Anticancer Drugs Market
8.2.1. U.S. Anticancer Drugs Market
8.2.1.1. Drug Type breakdown estimates & forecasts, 2017-2027
8.2.1.2. Therapy Type breakdown estimates & forecasts, 2017-2027
8.2.1.3. Cancer Type breakdown estimates & forecasts, 2017-2027
8.2.2. Canada Anticancer Drugs Market
8.3. Europe Anticancer Drugs Market Snapshot
8.3.1. U.K. Anticancer Drugs Market
8.3.2. Germany Anticancer Drugs Market
8.3.3. France Anticancer Drugs Market
8.3.4. Spain Anticancer Drugs Market
8.3.5. Italy Anticancer Drugs Market
8.3.6. Rest of Europe Anticancer Drugs Market
8.4. Asia-Pacific Anticancer Drugs Market Snapshot
8.4.1. China Anticancer Drugs Market
8.4.2. India Anticancer Drugs Market
8.4.3. Japan Anticancer Drugs Market
8.4.4. Australia Anticancer Drugs Market
8.4.5. South Korea Anticancer Drugs Market
8.4.6. Rest of Asia Pacific Anticancer Drugs Market
8.5. Latin America Anticancer Drugs Market Snapshot
8.5.1. Brazil Anticancer Drugs Market
8.5.2. Mexico Anticancer Drugs Market
8.6. Rest of The World Anticancer Drugs Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. F. Hoffmann-La Roche Ltd
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Industry Summary
9.2.1.5. Recent Developments
9.2.2. Eli Lilly and Company
9.2.3. Novartis AG
9.2.4. Pfizer Inc
9.2.5. Bayer AG
9.2.6. AstraZeneca
9.2.7. Takeda Pharmaceutical Company Limited
9.2.8. Merck & Co., Inc.
9.2.9. CELGENE CORPORATION
9.2.10. Amgen Inc
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research AssumptionList of Tables
TABLE 1. GLOBAL ANTICANCER DRUGS MARKET, REPORT SCOPE
TABLE 2. GLOBAL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY REGION 2017-2027 (USD BILLION)
TABLE 3. GLOBAL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY DRUG TYPE 2017-2027 (USD BILLION)
TABLE 4. GLOBAL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY THERAPY TYPE 2017-2027 (USD BILLION)
TABLE 5. GLOBAL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY CANCER TYPE 2017-2027 (USD BILLION)
TABLE 6. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 7. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 8. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 9. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 10. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 11. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 12. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 13. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 14. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 15. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 16. U.S. ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 17. U.S. ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 18. U.S. ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 19. CANADA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 20. CANADA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 21. CANADA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 22. UK ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 23. UK ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 24. UK ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 25. GERMANY ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 26. GERMANY ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 27. GERMANY ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 28. ROE ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 29. ROE ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 30. ROE ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 31. CHINA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 32. CHINA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 33. CHINA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 34. INDIA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 35. INDIA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 36. INDIA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 37. JAPAN ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 38. JAPAN ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 39. JAPAN ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 40. ROAPAC ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 41. ROAPAC ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 42. ROAPAC ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 43. BRAZIL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 44. BRAZIL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 45. BRAZIL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 46. MEXICO ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 47. MEXICO ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 48. MEXICO ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 49. ROLA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 50. ROLA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 51. ROLA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 52. ROW ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 53. ROW ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 54. ROW ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 55. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL ANTICANCER DRUGS MARKET
TABLE 56. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL ANTICANCER DRUGS MARKET
TABLE 57. YEARS CONSIDERED FOR THE STUDY
TABLE 58. EXCHANGE RATES CONSIDEREDList of Figures
FIG 1. GLOBAL ANTICANCER DRUGS MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL ANTICANCER DRUGS MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL ANTICANCER DRUGS MARKET, KEY TRENDS 2019
FIG 5. GLOBAL ANTICANCER DRUGS MARKET, GROWTH PROSPECTS 2020-2027
FIG 6. GLOBAL ANTICANCER DRUGS MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL ANTICANCER DRUGS MARKET, PEST ANALYSIS
FIG 8. GLOBAL ANTICANCER DRUGS MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 10. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 11. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 12. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 13. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 14. GLOBAL ANTICANCER DRUGS MARKET, REGIONAL SNAPSHOT 2017 & 2027
FIG 15. NORTH AMERICA ANTICANCER DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 16. EUROPE ANTICANCER DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 17. ASIA PACIFIC ANTICANCER DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 18. LATIN AMERICA ANTICANCER DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 19. GLOBAL ANTICANCER DRUGS MARKET, COMPANY MARKET SHARE ANALYSIS (2019)
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
Novartis AG
Pfizer Inc
Bayer AG
AstraZeneca
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
CELGENE CORPORATION
Amgen Inc
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports